Last reviewed · How we verify
Individual ATG — Competitive Intelligence Brief
marketed
Polyclonal antithymocyte globulin (immunosuppressant)
T lymphocytes (CD2, CD3, CD4, CD8, CD25 antigens)
Immunology
Small molecule
Live · refreshed every 30 min
Target snapshot
Individual ATG (Individual ATG) — The First Affiliated Hospital of Soochow University. ATG (anti-thymocyte globulin) is a polyclonal antibody that depletes T lymphocytes to suppress immune responses.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Individual ATG TARGET | Individual ATG | The First Affiliated Hospital of Soochow University | marketed | Polyclonal antithymocyte globulin (immunosuppressant) | T lymphocytes (CD2, CD3, CD4, CD8, CD25 antigens) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Polyclonal antithymocyte globulin (immunosuppressant) class)
- The First Affiliated Hospital of Soochow University · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Individual ATG CI watch — RSS
- Individual ATG CI watch — Atom
- Individual ATG CI watch — JSON
- Individual ATG alone — RSS
- Whole Polyclonal antithymocyte globulin (immunosuppressant) class — RSS
Cite this brief
Drug Landscape (2026). Individual ATG — Competitive Intelligence Brief. https://druglandscape.com/ci/individual-atg. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab